Interestingly, the combination treatment not only escalated the levels of pro-apoptotic protein, caspase-3, as well as caused Poly (ADP-ribose) polymerase (PARP) cleavage (Figure 4C) but also mitigated the levels of various cancer-promoting proteins in myeloma cells (Figure 4D). This evidence concerns the gene CASP3 and plasma cell myeloma.